VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | Updates from CheckMate 040 in Asian HCC patients

VJOncology is committed to improving our service to you

Thomas Yau

Thomas Yau, MD, MBBS, MRCP, FRCP, of the University of Hong Kong, Hong Kong, China, discusses the efficacy and safety of nivolumab and ipilumumab in Asian patients with advanced hepatocellular carcinoma (HCC) as evaluated in the CheckMate 040 study (NCT01658878). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter